HN30
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome. The company was formerly known as Nova Mentis Life… Read more
HN30 (HN30) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.532x
Based on the latest financial reports, HN30 (HN30) has a cash flow conversion efficiency ratio of 0.532x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-78.87K) by net assets (€-148.32K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
HN30 - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how HN30's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
HN30 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HN30 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
REPUBLIC SERVICES (RPU.SG)
STU:RPU
|
0.089x |
|
RanLOS AB Series B
ST:RLOS-B
|
N/A |
|
Cortus Energy AB (publ)
ST:CE
|
-1.732x |
|
OCEAN-GEOLOOP AS NK -01
F:FQ4
|
N/A |
|
Current Water Technologies Inc
PINK:ENPRF
|
-0.016x |
|
BIORA THERAPEUT.NEW -001
F:4ZU0
|
N/A |
|
Marvel Discovery Corp
OTCQB:MARVF
|
0.023x |
|
HERSHEY - Dusseldorf Stock Exchang
DU:HSY
|
0.165x |
Annual Cash Flow Conversion Efficiency for HN30 (2021–2024)
The table below shows the annual cash flow conversion efficiency of HN30 from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-299.07K | €-71.77K | 0.240x | -29.91% |
| 2023-12-31 | €-810.60K | €-277.53K | 0.342x | +100.59% |
| 2022-12-31 | €41.34K | €-2.41 Million | -58.281x | -1274.84% |
| 2021-12-31 | €459.10K | €-1.95 Million | -4.239x | -- |